Additional considerations include: Gastrointestinal effects : Wegovy commonly causes nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
It works by reducing appetite, increasing feelings of fullness, slowing gastric emptying, boosting insulin release when blood sugar is high, and reducing glucagon secretion
This finding is relevant to alternating because repeated switching could theoretically compound vestibular effects
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
levels below 400 pg/mL may affect hair despite being normal range. Complete Blood Count (CBC) screens for anemia, which dramatically impacts hair growth
This process is especially common with GLP-1 medications like Wegovy, Zepbound, and Ozempic, due to their high cost and increasing demand